The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Background: Clinical trial designs have historically been biased towards the Caucasian population, with limited ...

The Multicenter Osteoarthritis (MOST) study, which is looking for modifiable risk factors for knee osteoarthritis, is ...

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

We reached out to experts to find out how many hours of sleep women actually need, and what can impact their ability to get ...

The African Medical Centre of Excellence (AMCE) officially opened today, marking a historic milestone in Africa's journey ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...